Latest News
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pelacarsen did not meet its primary endpoint of reduci...
Aptar and Aceso Therapeutics partner to advance inhaled cystic fibrosis therapy
7 September 2026 - Aptar Pharma, a provider of drug delivery, dosing, protection technologies and services and part of AptarGroup Inc (NYSE:ATR), announced on Monday that it has partnered with Aceso Therapeutics, a biotech developing novel therapies ...
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
7 September 2026 - Precision oncology company Guardant Health Inc (Nasdaq:GH) announced on Friday that the US Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH (camizestrant) in p...
4basebio announces expansion of DNA offering for personalised mRNA medicines
7 September 2026 - Synthetic DNA 4basebio PLC (AIM: 4BB) declared on Monday that it has expanded its DNA offering to support production of critical starting material for personalised mRNA medicines.The expanded offering across the company's high...
Clover Biopharmaceuticals reports positive Phase 2 trial data for respiratory combination vaccine candidates
7 September 2026 - Chinese biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) announced on Sunday positive preliminary data from a Phase 2 clinical trial in older adults in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + ...